- Home
- DRDB vs ABEO Comparison
DRDB vs ABEO Comparison
Compare DRDB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$6.36
Company Overview
Basic Information| Metric | DRDB | ABEO |
|---|---|---|
| Founded | 2024 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.5M | 320.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | DRDB | ABEO |
|---|---|---|
| Price | $10.55 | $6.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 98.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | $597.54 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $10.25 | $4.00 |
| 52 Week High | $10.56 | $7.54 |
Technical Indicators
Market Signals| Indicator | DRDB | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 65.47 | 68.60 |
| Support Level | $10.50 | $5.19 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.01 | 0.25 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 100.00 | 97.81 |
Price Performance
Historical Comparison DRDB
ABEO
About DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.